purposeth
threat
smallpox
result
bioterrorist
action
prompt
reassess
level
immun
current
popul
examin
magnitud
durat
antivir
antibodi
immun
confer
smallpox
vaccin
particip
baltimor
longitudin
studi
age
popul
subject
vaccin
one
time
year
evalu
store
serum
sampl
avail
variou
interv
vaccin
addit
subject
document
childhood
smallpox
infect
subject
histori
infect
vaccin
includ
quantifi
total
vaccinia
igg
neutral
antibodi
titer
subgroup
particip
time
resultsvaccin
particip
maintain
antivaccinia
igg
neutral
antibodi
titer
natur
log
essenti
indefinit
absolut
titer
antivaccinia
antibodi
slightli
higher
multipl
vaccin
particip
decreas
vacciniaspecif
antibodi
titer
note
age
followup
period
year
moreov
baltimor
longitudin
studi
age
particip
surviv
activ
smallpox
infect
youth
retain
antivaccinia
antibodi
titer
similar
level
detect
vaccin
subject
conclusionthes
data
suggest
multipl
recent
vaccin
essenti
maintain
vacciniaspecif
antibodi
respons
human
subject
scarc
vaccin
suppli
appli
first
individu
previous
vaccin
author
reassess
level
immun
current
popul
evalu
risk
benefit
revaccin
program
given
major
american
age
year
never
vaccin
smallpox
great
major
receiv
booster
vaccin
sinc
earli
immun
smallpox
consid
low
nonexist
today
popul
past
primari
vaccin
individu
vaccinia
believ
confer
depend
protect
least
year
increas
protect
achiev
subsequ
revaccin
howev
major
question
pose
today
whether
individu
vaccin
year
ago
would
protect
event
smallpox
exposur
may
critic
question
avail
smallpox
vaccin
limit
current
inadequ
mass
inocul
program
address
evalu
stabil
potenc
vacciniaspecif
immun
smallpox
vaccin
individu
particip
nation
institut
age
baltimor
longitudin
studi
age
longitudin
studi
advantag
cohort
studi
allow
multipl
measur
individu
time
subject
includ
studi
particip
nation
institut
age
baltimor
longitudin
studi
age
blsa
longitudin
studi
norm
age
establish
continu
gather
extens
inform
health
physiolog
function
cohort
individu
examin
year
interv
depend
age
blsa
particip
fast
serum
sampl
bank
visit
includ
studi
subset
total
blsa
cohort
known
histori
either
smallpox
infect
n
document
smallpox
vaccin
n
also
includ
nonvaccin
blsa
particip
blsa
particip
previous
vaccin
serum
sampl
avail
store
year
median
year
first
vaccin
median
number
sampl
per
subject
rang
vaccin
histori
verifi
medic
militari
record
usual
inform
number
vaccin
document
one
sourc
substudi
blsa
approv
institut
review
board
particip
sign
inform
consent
antivaccinia
antibodi
determin
serum
specimen
enzymelink
immunosorb
assay
elisa
viru
neutral
assay
vaccinia
neutral
assay
perform
use
modif
publish
protocol
serial
dilut
sera
start
dilut
incub
pfu
green
fluoresc
proteinexpress
vaccinia
virusinfect
cell
final
concentr
pfu
per
cell
plate
fluoresc
intens
infect
cell
compar
well
contain
cell
viru
serum
posit
control
cell
serum
contain
viru
background
control
neutral
nt
defin
reciproc
serum
dilut
requir
reduct
green
fluoresc
protein
express
appar
vacciniainfect
cell
logarithm
transform
data
use
calcualt
titer
neg
serum
control
run
assay
sampletosampl
variat
titer
typic
deviat
titer
dilut
sampl
repeat
run
addit
vig
mgml
use
intern
refer
standard
establish
standard
demonstr
nt
titer
calcul
neutral
concentr
vig
ml
vig
statist
analys
perfom
use
sa
softwar
version
sa
institut
inc
cari
nc
vacciniaspecif
igg
nt
titer
convert
natur
logarithm
normal
distribut
regress
repeatedmeasur
linear
mixedeffect
analys
use
determin
signific
chang
time
variabl
vaccin
differ
antibodi
titer
subject
vaccin
relationship
log
vacciniaspecif
igg
nt
titer
p
valu
consid
statist
signific
subject
select
total
blsa
popul
includ
subject
document
histori
one
smallpox
vaccin
n
known
histori
small
pox
infect
n
addit
subject
includ
histori
smallpox
vaccin
infect
tabl
latter
group
gener
younger
born
smallpox
vaccin
longer
recommend
practic
among
individu
prior
vaccin
n
vacciniaspecif
igg
titer
persist
remain
rel
stabl
variou
assess
time
point
titer
rang
ln
period
year
initi
vaccin
figur
comparison
antivir
antibodi
igg
titer
elicit
addit
vaccin
demonstr
small
statist
signific
p
increas
mean
igg
titer
produc
vaccin
compar
subject
receiv
one
vaccin
addit
vaccin
inocul
result
small
signific
increas
igg
mainten
titer
year
final
vaccin
administr
figur
igg
titer
demonstr
persist
vacciniareact
antibodi
indic
antibodi
abil
neutral
viral
infect
assess
viral
neutral
antibodi
use
modifi
vaccinia
neutral
assay
similar
igg
titer
vacciniaspecif
neutral
antibodi
level
quit
stabl
singl
multipl
vaccin
year
figur
major
examin
sampl
nt
rang
ln
remain
stabl
patient
measur
neutral
antibodi
note
contrast
elisa
find
signific
differ
neutral
antibodi
level
vaccin
compar
receiv
addit
vaccin
figur
control
nonvaccin
subject
reproduc
yield
nt
titer
ln
major
sampl
reproduc
measur
ln
also
assess
stabil
sequenti
measur
neutral
antibodi
among
subject
receiv
singl
vaccin
median
line
valu
obtain
subject
small
neg
slope
data
shown
suggest
even
individu
singl
vaccin
maintain
protect
level
neutral
antibodi
indefinit
overal
data
document
persist
vacciniaspecif
antibodi
level
extend
time
period
initi
subsequ
vaccin
nearli
vaccin
donor
smallpox
infect
survivor
known
lifelong
protect
reinfect
expect
therefor
individu
histori
infect
would
higher
level
immun
mere
vaccin
howev
found
differ
antivaccinia
antibodi
titer
patient
recov
smallpox
subject
vaccin
one
time
vaccinia
subject
prior
histori
smallpox
retain
vacciniaspecif
igg
neutral
titer
similar
subject
vaccin
one
time
lifetim
figur
extinct
natur
occur
smallpox
may
imposs
definit
establish
immunolog
correl
protect
diseas
human
base
older
data
titer
reason
biomark
protect
immun
result
demonstr
sampl
test
exhibit
neutral
titer
time
point
test
less
donor
demonstr
titer
initi
subsequ
fell
cutoff
valu
similarli
subject
previous
diagnos
smallpox
possess
lifelong
protect
smallpox
viru
also
use
threshold
lowest
neutral
titer
blsa
particip
document
medic
histori
smallpox
infect
titer
found
use
level
neutral
antibodi
marker
smallpox
resist
found
subject
demonstr
titer
level
sampl
examin
longitudin
studi
durabl
immun
respons
vaccinia
immun
suggest
nearli
individu
vaccin
maintain
specif
neutral
antivaccinia
antibodi
level
suggest
protect
smallpox
multipl
vaccin
produc
slightli
higher
level
antibodi
level
antibodi
decreas
significantli
time
vaccin
dogma
smallpox
vaccin
individu
repeat
exposur
smallpox
eg
travel
endem
countri
revaccin
everi
year
howev
sever
crosssect
epidemiolog
studi
suggest
smallpox
vaccin
provid
recipi
protect
lethal
smallpox
longer
period
time
multipl
inocul
might
necessari
longitudin
data
support
argument
singl
vaccin
elicit
function
antibodi
remain
stabl
lifetim
specif
role
humor
cellular
immun
longterm
protect
smallpox
complet
defin
prospect
studi
indic
high
level
neutral
antibodi
may
associ
protect
immun
smallpox
one
studi
demonstr
subject
contact
smallpox
victim
possess
vaccinia
viru
neutral
titer
suscept
smallpox
infect
contact
infect
compar
subject
antibodi
titer
contact
infect
smaller
studi
contact
neutral
titer
contract
smallpox
wherea
contat
titer
higher
contract
diseas
thu
serumneutr
antibodi
level
might
use
least
biomark
protect
immun
regardless
whether
protect
mediat
humor
cellular
immun
studi
hammarlund
et
al
volunt
vaccin
age
year
retain
substanti
humor
tcell
immun
vaccinia
viru
antivir
antibodi
respons
present
year
vaccin
antivaccinia
tcell
respons
decreas
year
last
vaccin
anoth
studi
found
virusspecif
tcell
memori
persist
year
presum
absenc
antigen
similarli
observ
mainten
high
level
circul
antivaccinia
antibodi
mani
differ
time
point
individu
life
span
period
contrast
studi
hsieh
cowork
reveal
longev
vacciniaspecif
tcellspecif
immun
memori
cohort
taiwanes
individu
age
year
easili
detect
subject
previous
vaccin
year
earlier
difficult
detect
subject
vaccin
year
earlier
find
differ
somewhat
report
vacciniareact
cell
could
detect
long
year
vaccin
reason
differ
remain
unclear
recent
studi
healthi
previous
vaccin
adult
age
year
revaccin
clinic
take
skin
reactiv
vaccin
found
seroconvert
subject
clinic
take
demonstr
littl
antibodi
respons
moreov
level
preexist
antibodi
invers
correl
rate
clinic
take
seroconvers
group
vaccine
lowest
preexist
level
antibodi
develop
antibodi
responses
vaccin
challeng
studi
also
demonstr
time
sinc
last
vaccin
significantli
associ
rate
clinic
take
antibodi
seroconvers
longer
interv
sinc
last
vaccin
greater
rate
clinic
take
seroconvers
unfortun
longitudin
studi
precis
inform
clinic
take
retain
extand
time
period
howev
small
cohort
subject
document
demonstr
similar
antibodi
mainten
pattern
subject
without
document
dada
shown
individu
surviv
smallpox
infect
thought
maintain
lifelong
protect
contrast
vaccin
gener
induc
respons
diminish
time
thu
expect
individu
histori
infect
would
higher
level
immun
vaccin
howev
found
vacciniaspecif
antibodi
titer
compar
group
figur
mechan
lifelong
persist
vacciniaelicit
smallpox
immun
undefin
morbid
associ
vaccin
administr
risk
mortal
among
elderli
immunecompromis
popul
also
critic
factor
influenc
vaccin
polici
littl
inform
avail
safeti
efficaci
smallpox
vaccin
elderli
popul
furthermor
age
process
associ
immun
respons
abnorm
develop
immun
guidelin
popul
need
consid
factor
protect
popul
smallpox
face
limit
suppli
vaccin
may
challeng
frey
et
al
shown
dilut
vaccin
also
highli
effici
elicit
clinic
take
previous
unvaccin
individu
reveal
nearli
individu
vaccin
one
time
maintain
antivaccinia
igg
neutral
antibodi
titer
natur
log
indefinit
titer
stabl
year
moreov
surviv
activ
smallpox
infect
youth
retain
vacciniaspecif
immun
throughout
live
antivaccinia
antibodi
titer
similar
level
vaccin
subject
thu
vaccin
subject
remain
immun
vaccinia
indefinit
requir
booster
vaccin
even
mani
decad
remov
primari
vaccin
data
impli
limit
suppli
vaccin
use
appli
perhap
dilut
form
individu
never
vaccin
primarili
individu
born
vaccinia
elicit
antivir
antibodi
level
viru
neutral
activ
remain
elev
life
patient
multipl
vaccin
achiev
margin
higher
level
antibodi
viru
neutral
activ
singl
vaccin
level
antibodi
viru
neutral
activ
compar
vaccin
individu
develop
smallpox
recov
vaccinia
use
first
individu
never
vaccin
comparison
natur
log
vacciniaspecif
igg
neutral
titer
among
particip
singl
vaccin
multipl
vaccin
previou
smallpox
diagnosi
bar
show
averag
se
antibodi
product
group
vacciniaspecif
igg
neutral
b
titer
particip
previou
smallpox
diagnosi
significantli
differ
titer
particip
singl
multipl
vaccin
howev
similar
figur
vacciniaspecif
igg
respons
significantli
p
differ
singli
versu
multipli
vaccin
baltimor
longitudin
studi
age
subject
particip
select
base
medic
histori
document
vaccin
statu
interv
sinc
last
vaccin
mani
subject
number
serum
sampl
bank
year
interv
extend
time
period
sampl
select
vacciniaspecif
igg
neutral
antibodi
respons
could
examin
year
interv
last
vaccin
control
nonvaccin
subject
also
recruit
studi
eight
particip
blsa
studi
diagnos
smallpox
youth
smapl
subject
also
examin
assess
presenc
vacciniareact
antibodi
sampl
screen
titer
vacciniaspecif
igg
neutral
antibodi
level
